Horizon Therapeutics Public Ltd Co: directors' dealings · United States · SEC (Form 4)

About Horizon Therapeutics Public Ltd Co

Horizon Therapeutics Public Ltd Co (ticker HZNP) was a U.S.-focused biopharmaceutical company listed on the Nasdaq in the United States and built around specialty medicines for rare, autoimmune, and severe inflammatory diseases. The company was founded in 2005 in Illinois and later moved its legal headquarters to Ireland through a tax inversion, while its commercial footprint and revenue base remained heavily concentrated in the U.S. For investors, Horizon is best understood as a highly focused specialty pharma platform rather than a broad diversified pharmaceutical group. Its business model centered on discovering, developing, and commercializing medicines for medically underserved patient populations. Horizon’s core commercial franchises were TEPEZZA for thyroid eye disease, KRYSTEXXA for chronic refractory gout, and UPLIZNA for certain rare autoimmune indications. The portfolio also included RAVICTI, PROCYSBI, ACTIMMUNE, PENNSAID 2%, and DUEXIS, reflecting a mix of growth assets and established specialty products. In its 2022 annual report, Horizon described itself as a global biotechnology company targeting critical needs in rare, autoimmune, and severe inflammatory diseases, with a portfolio that was meaningfully international even though the business remained overwhelmingly U.S.-driven. From a competitive standpoint, Horizon’s edge came from deep expertise in specialty commercialization: reaching disease specialists, building physician awareness, supporting patient identification and adherence, and expanding labels through clinical data generation. That model gave Horizon a stronger moat than many small-cap biotechs, because its products addressed narrow, high-unmet-need markets where execution and clinical differentiation matter more than mass-market scale. At the same time, the company was exposed to concentration risk because a limited number of molecules accounted for much of its growth and investor attention. Prior to its takeout, TEPEZZA, KRYSTEXXA, and UPLIZNA were the main revenue drivers and the clearest indicators of platform strength. The most important recent corporate event is that Amgen announced and completed the acquisition of Horizon, closing on October 6, 2023, for approximately $27.8 billion in cash. As a result, Horizon is no longer an independently traded company, and references to HZNP in SEC Form 4 filings are mainly historical insider-transaction records from before the transaction closed. In strategic terms, Horizon became a notable rare-disease success story that created substantial value through specialty product commercialization before being absorbed by a larger U.S. pharmaceutical company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1492426/000095017023005337/hznp-20221231.htm?utm_source=openai))